home / stock / cycc / cycc quote
Last: | $1.63 |
---|---|
Change Percent: | -1.81% |
Open: | $1.66 |
Close: | $1.66 |
High: | $1.66 |
Low: | $1.61 |
Volume: | 32,515 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.63 | $1.66 | $1.66 | $1.66 | $1.61 | 32,515 | 07-03-2024 |
$1.66 | $1.67 | $1.66 | $1.67 | $1.6 | 14,085 | 07-02-2024 |
$1.62 | $1.66 | $1.62 | $1.72 | $1.57 | 65,492 | 07-01-2024 |
$1.62 | $1.74 | $1.62 | $1.75 | $1.5533 | 74,079 | 06-28-2024 |
$1.7 | $1.79 | $1.7 | $1.8398 | $1.6492 | 141,021 | 06-27-2024 |
$1.9005 | $1.72 | $1.9005 | $2 | $1.68 | 942,841 | 06-26-2024 |
$1.59 | $1.67 | $1.59 | $1.74 | $1.55 | 59,952 | 06-25-2024 |
$1.6624 | $1.73 | $1.6624 | $1.8 | $1.6401 | 48,078 | 06-24-2024 |
$1.75 | $1.63 | $1.75 | $1.83 | $1.62 | 232,813 | 06-21-2024 |
$1.65 | $1.53 | $1.65 | $1.6999 | $1.48 | 75,133 | 06-20-2024 |
$1.5 | $1.59 | $1.5 | $1.63 | $1.45 | 56,790 | 06-19-2024 |
$1.5 | $1.59 | $1.5 | $1.63 | $1.45 | 56,790 | 06-18-2024 |
$1.63 | $1.69 | $1.63 | $1.69 | $1.55 | 38,591 | 06-17-2024 |
$1.69 | $1.7 | $1.69 | $1.71 | $1.6509 | 26,509 | 06-14-2024 |
$1.65 | $1.68 | $1.65 | $1.77 | $1.65 | 60,170 | 06-13-2024 |
$1.7 | $1.8 | $1.7 | $1.8 | $1.68 | 105,519 | 06-12-2024 |
$1.85 | $1.87 | $1.85 | $1.9988 | $1.82 | 30,307 | 06-11-2024 |
$1.88 | $1.94 | $1.88 | $2.07 | $1.85 | 154,912 | 06-10-2024 |
$2 | $1.95 | $2 | $2.03 | $1.95 | 57,204 | 06-07-2024 |
$1.98 | $2.09 | $1.98 | $2.15 | $1.95 | 62,701 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...